Amphastar Pharmaceuticals (AMPH) PT Lowered to $21 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AMPH Hot Sheet
Price: $27.72 --0%
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Join SI Premium – FREE
Piper Sandler analyst David Amsellem lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $21.00 (from $25.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Macquarie Upgrades Manila Electric Co. (MER:PM) (MAEOY) to Outperform
- Fortrea (FTRE) PT Raised to $26 at TD Cowen
- Regeneron Pharma (REGN) PT Raised to $1,030 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
